Skip to main content

Table 3 Frequencies of different cell populations in SLE patients and healthy controls

From: Protein synthesis of the pro-inflammatory S100A8/A9 complex in plasmacytoid dendritic cells and cell surface S100A8/A9 on leukocyte subpopulations in systemic lupus erythematosus

Cell population Healthy controls (median and 95% CI) 1 SLE patients (median and 95% CI) P-value
CD3 + T cells 60.9 (57.8 to 63.9) 65.1 (55.7 to 64.3) 0.42
CD4 + T cells 62.1 (57.0 to 64.7) 55.2 (51.3 to 58.9) 0.06
CD4 + HLA-DR + 6.5 (5.3 to 7.2) 31.3 (24.9 to 36.9) 0.001
CD8 + T cells 15.7 (14.3 to 18.8) 20.4 (18.6 to 24.0) 0.02
CD8 + HLA-DR + 40.8 (39.0 to 43.2) 36.9 (33.4 to 41.5) 0.33
BDCA-1 + mDCs 0.40 (0.34 to 0.46) 0.31 (0.28 to 0.62) 0.19
BDCA-2 + pDCs 0.07 (0.07 to 0.11) 0.09 (0.09 to 0.16) 0.39
CD14 ++ CD16 - monocytes 10.1 (9.6 to 13.3) 16.9 (16.0 to 25.2) 0.013
CD14 ++ CD16 + monocytes 0.17 (0.15 to 0.27) 0.30 (0.44 to 0.81) 0.003
CD19 + B cells 5.6 (4.7 to 6.3) 5.1 (5.0 to 7.8) 0.78
CD19 + CD27 + IgD - CD38 + CD20 - 0.43 (0.35 to 0.75) 1.0 (0.8 to 3.0) < 0.0001
  1. 1For CD3+ T cells, dendritic cells, monocytes and B cells the percentage is calculated against the total leukocyte count. For all subpopulations, the percentage is calculated against the main population (for example, CD4+ T cells for all CD4+ T cell analyses).
  2. CI, confidence interval; HLA, human leukocyte antigen; mDC, myeloid dendritic cell; pDC, plasmacytoid dendritic cell